0JDK Stock Overview
A commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Iovance Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.57 |
| 52 Week High | US$15.48 |
| 52 Week Low | US$3.43 |
| Beta | 0.93 |
| 1 Month Change | -38.16% |
| 3 Month Change | -52.02% |
| 1 Year Change | -76.22% |
| 3 Year Change | -78.96% |
| 5 Year Change | n/a |
| Change since IPO | -73.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JDK | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -0.6% | 0.2% | 0.2% |
| 1Y | -76.2% | -11.7% | 6.3% |
Return vs Industry: 0JDK underperformed the UK Biotechs industry which returned -11.7% over the past year.
Return vs Market: 0JDK underperformed the UK Market which returned 6.3% over the past year.
Price Volatility
| 0JDK volatility | |
|---|---|
| 0JDK Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.0% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0JDK's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0JDK's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 838 | Frederick Vogt | www.iovance.com |
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer NSCLC and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers.
Iovance Biotherapeutics, Inc. Fundamentals Summary
| 0JDK fundamental statistics | |
|---|---|
| Market cap | US$1.16b |
| Earnings (TTM) | -US$372.18m |
| Revenue (TTM) | US$164.07m |
7.1x
P/S Ratio-3.1x
P/E RatioIs 0JDK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JDK income statement (TTM) | |
|---|---|
| Revenue | US$164.07m |
| Cost of Revenue | US$124.00m |
| Gross Profit | US$40.08m |
| Other Expenses | US$412.25m |
| Earnings | -US$372.18m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 24.43% |
| Net Profit Margin | -226.84% |
| Debt/Equity Ratio | 0.1% |
How did 0JDK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 18:07 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Iovance Biotherapeutics, Inc. is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Madhu Kumar | Baird |
| Peter Lawson | Barclays |